Alnylam Income Tax Expense from 2010 to 2024

ALNY Stock  USD 253.07  0.67  0.26%   
Alnylam Pharmaceuticals Income Tax Expense yearly trend continues to be fairly stable with very little volatility. Income Tax Expense is likely to outpace its year average in 2024. During the period from 2010 to 2024, Alnylam Pharmaceuticals Income Tax Expense regression line of annual values had r-squared of  0.21 and arithmetic mean of (7,354,317). View All Fundamentals
 
Income Tax Expense  
First Reported
2003-03-31
Previous Quarter
5.7 M
Current Value
2.9 M
Quarterly Volatility
6.2 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 56.8 M, Interest Expense of 127.3 M or Other Operating Expenses of 2.2 B, as well as many indicators such as Price To Sales Ratio of 12.42, Dividend Yield of 0.0 or Days Sales Outstanding of 63.31. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Latest Alnylam Pharmaceuticals' Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Alnylam Pharmaceuticals over the last few years. It is Alnylam Pharmaceuticals' Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Slightly volatile
   Income Tax Expense   
       Timeline  

Alnylam Income Tax Expense Regression Statistics

Arithmetic Mean(7,354,317)
Geometric Mean4,194,147
Coefficient Of Variation(195.87)
Mean Deviation11,727,922
Median(86,000)
Standard Deviation14,404,715
Sample Variance207.5T
Range47.3M
R-Value0.46
Mean Square Error175.7T
R-Squared0.21
Significance0.08
Slope1,488,660
Total Sum of Squares2904.9T

Alnylam Income Tax Expense History

20247.1 M
20236.7 M
20224.2 M
2021680 K
20202.7 M
2019863 K
2018823 K

About Alnylam Pharmaceuticals Financial Statements

Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' Income Tax Expense, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Tax Expense6.7 M7.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.